DOI:
10.1055/s-00032260
Digestive Disease Interventions
LinksClose Window
References
Fukuoka S, Hara H, Takahashi N. et al.
Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).
J Clin Oncol 2019;
37: 2522-2522
We do not assume any responsibility for the contents of the web pages of other providers.